Pyrilutamide (KX-826) is discussed as an anti-androgen treatment for hair loss, with mixed user experiences. Some users report no results, while others find it mildly effective.
The user shares their experience with hair loss treatments, specifically finasteride, and discusses the side effects like lowered libido and motivation. They recommend trying tyrosine to counter these effects, noting it improved their libido and energy levels.
The conversation discusses verteporfin as a potential treatment for hair regeneration, which could lead to unlimited hair transplants by healing the donor area. Some users are considering using verteporfin now, while others are hopeful it will be available for future hair transplants.
Hope Medicine's HMI-115 is expected to be released in 2027, with phase 3 trials currently recruiting. Concerns include the safety of targeting prolactin and the potential cost of the treatment.
The conversation is about finding a clearnet vendor for clascoterone, also known as Winlevi, for hair loss treatment. The user is seeking recommendations via direct message.
The post discusses the potential of GT20029 in treating hair loss, questioning if it will replace finasteride or be used alongside existing treatments. A reply indicates that its role is still uncertain.
The user is using oral and topical minoxidil, finasteride, dutasteride, and considering adding rosemary and pumpkin saw palmetto to their regimen. They report significant hair growth, especially with dutasteride, and are considering increasing their dose and adding RU58841.
The conversation discusses experiences with hair loss treatments containing RootBioTec and Anagain. Users share their results and compare these treatments to Minoxidil, finasteride, and RU58841.
HMI 115 is being discussed as a potential hair loss treatment, with skepticism due to past disappointments like cosmeRNA, brezula, and pyrilutamide. The user is questioning if they should be hopeful for new developments in the next six years.
New hair loss treatments like Shiseido/Replicel and Histogen were discussed, with cautious optimism about their availability by 2018. Setipiprant, Replicel, and Bimatoprost were mentioned as potential treatments expected around 2016-2017.
Dr. Bloxham's new channel will discuss verteporfin and other future hair loss treatments. Users express interest and hope for the effectiveness of these treatments.
Veradermics' extended-release oral minoxidil is expected to be commercially available in 2027-2028, while another company, Minx, may release a similar product sooner. VDPHL01 is considered more clinically validated compared to Minx.
The potential of verteporfin to heal wounds without scarring; however, despite its promising preclinical trials and coverage from a major media outlet, there is still no official clinical trial result and the drug has only garnered attention from hair loss communities.
Scube3, a potential hair loss treatment, is unlikely to be released because it was given to a startup company, Amplifica, which may go bankrupt and fail to bring the treatment to market. Amplifica is prioritizing other treatments over Scube3, which could lead to financial loss and the end of Scube3's development.
PP405 may reactivate dormant hair follicles but won't replace hair transplants or resurrect dead follicles. Its effectiveness, cost, and impact compared to treatments like minoxidil and finasteride are uncertain.
A user humorously discusses hair loss, using treatments like Dutasteride, Finasteride, Minoxidil, and RU58841, and jokingly considers satanic rituals as a solution. The conversation includes satirical responses about trading one's soul for hair.
The conversation is about finding a source for sterile dutasteride for mesotherapy to avoid side effects from oral 5AR blockers. The user is currently using microneedling and 0.01% topical dutasteride and plans to use transplants.
A user who is using Pyrilutamide, Finasteride, and a homemade topical solution to treat their hair loss. Replies mentioned the potential of Pyrilutamide being a "cure" for hair loss and a reminder that results may not be credited solely to it.
The conversation is optimistic about future hair loss treatments, highlighting Veradermics, Breezula, and PP405 as promising options expected by 2027-2028. The user expresses hope that these developments will prevent future generations from experiencing the same struggles with hair loss.
PP405 is the most promising future treatment for hair loss, aiming to reactivate dormant hair follicles. Clascoterone 5% is the most promising near-term drug, while current strategies include using finasteride or dutasteride to stabilize hair loss and minoxidil to stimulate growth.
The conversation is about hair loss treatments, specifically a stack including topical Ashwagandha, Copper Peptide, Gotu Kola, Ketoconazole, and PDA. One user found Topical and Sub-Q GHK-CU effective.
A user's regimen to help with their diffuse thinning, which includes taking Pyrilutamide BID, 1mg finasteride daily, 2.5mg oral minoxidil daily, topical minoxidil since August 2021, LLLT every two days, topical fin, progesterone, melatonin, minoxidil (started one week ago), pumpkin seed oil and not dermarolling; other commenters suggested Nizoral for dandruff control and caution when using pre-mixed products with Pyrilutamide.
User discusses group buy for finerenone, a third-gen mineralocorticoid antagonist for hair loss treatment. Finerenone inhibits TGFb, NOX, and ROS, and improves renal and cardiac function; topical dose should be no more than 10mg per day.
A user with hair loss is considering starting a business selling hair loss treatments, including RU58841, low-dose topical finasteride with optional minoxidil and tretinoin, and topical melatonin. They are also contemplating offering Pyrilutamide and other unique topicals, seeking feedback on interest and suggestions for their potential store.
Adding non-prescription topicals like alfatradiol and Zix to a standard fin/min/niz regimen may help with scalp inflammation and shedding, but their long-term effectiveness varies. Zix is recommended for reducing scalp inflammation and enhancing the effectiveness of other treatments.
PP405 is a potential hair loss treatment that may reactivate dormant hair follicles, with Phase 3 trials expected. Some users are cautious, suggesting using finasteride in the meantime, while others are skeptical about PP405's effectiveness.
Kintor edited their Amazon page, removing claims that KX-826 provides "real" visible results from clinical experiments. The discussion includes treatments like Minoxidil, finasteride, and RU58841.
The conversation discusses the potential risks and considerations of purchasing raw Clascoterone powder from Made-In-China to create a DIY topical solution for hair loss. Concerns include fake products, low purity, and contamination, with a request for experiences and advice on reliable suppliers.